Stem Cell Therapy for Diabetic Foot Ulcers

This article looks at what the clinical research actually shows about using stem cells to treat diabetic foot ulcers (DFUs) — how the therapy is thought to work, what trials and meta-analyses have found about wound closure and amputation prevention, and where the science still falls short of proof, including current FDA approval status.

Why Diabetic Foot Ulcers Are Hard to Treat

Diabetic foot ulcers are slow-healing wounds caused by nerve damage, poor circulation, and impaired tissue repair in people with diabetes. They are stubborn: many don't close with standard wound care alone, and DFUs are described in the research literature as preceding the large majority of diabetes-related lower-limb amputations, which is why finding therapies that speed healing matters so much.

How It's Thought to Work

Stem cell therapy for DFUs typically uses mesenchymal stem cells (MSCs) drawn from a patient's own bone marrow or fat tissue, or from donated umbilical cord or placental tissue, delivered into or around the wound by injection or as part of a dressing. Rather than becoming new skin cells themselves, MSCs are thought to act mainly through paracrine signaling — releasing growth factors that encourage new blood vessel formation (angiogenesis), calm excess inflammation, and recruit the body's own repair cells to the wound bed. Some protocols use bone-marrow mononuclear cells or other cell mixtures instead of purified MSCs.

What the Evidence Shows

The strongest signal comes from pooled data. A 2026 analysis in Diabetes, Metabolic Syndrome and Obesity that cross-checked nine separate meta-analyses covering dozens of randomized controlled trials found that stem cell therapy was associated with significantly higher ulcer healing rates and significantly lower amputation rates than conventional care, with fewer adverse events in the stem cell groups — genuinely encouraging findings, though the count of underlying trials comes from that single paper's own accounting rather than an independently cross-verified figure. An earlier meta-analysis in Stem Cell Research & Therapy, pooling six randomized trials of autologous stem cells, reported a real healing benefit with no increase in treatment-related adverse events.

That said, the underlying trials are still small, and the picture isn't uniformly positive. A rigorous 2025 Phase 2 trial of placenta-derived cells (PDA-002) randomized 159 patients with DFUs complicated by peripheral artery disease and found a numerically higher complete wound-closure rate with active treatment (38.5% vs. 22.6% with placebo at one dose) — a promising trend — but the result did not reach statistical significance, likely because far more placebo patients healed than the trial's designers expected. Reviewers of the pooled meta-analyses have also flagged substantial overlap between studies and inconsistent quality across the underlying trials, urging caution before drawing firm conclusions.

Regulatory status matters too: no stem cell or other cell-based therapy is currently FDA-approved specifically for diabetic foot ulcers. Products remain in the investigational pipeline — for example, PolarityBio's SkinTE, an autologous cell-based skin construct, received FDA Breakthrough Therapy Designation for Wagner Grade I DFUs in February 2025 and completed a pivotal Phase 3 trial in late 2025, but it has not yet been approved.

Who Might Be a Candidate

• People with a diabetic foot ulcer that hasn't responded to weeks of standard care (debridement, offloading, infection control, dressings) may be candidates for a clinical trial evaluating stem cell therapy
• Candidates generally need adequate blood flow to the limb, since cell therapy is not a substitute for treating underlying peripheral artery disease
• Wounds with active, uncontrolled infection are typically excluded from trials until the infection is resolved
• Anyone considering this route should look specifically for enrollment in a registered clinical trial rather than an unregulated clinic offering "stem cell" injections, since no product is FDA-approved for this use
• Candidacy is best discussed with an endocrinologist, wound care specialist, or vascular surgeon familiar with the person's full diabetes and circulation history

Bottom Line

Across dozens of small-to-moderate randomized trials, stem cell therapy shows a real and fairly consistent signal of improving wound healing and possibly reducing amputation risk compared with standard diabetic foot ulcer care, and the safety profile so far looks reassuring. But the evidence base still rests mostly on small trials with real heterogeneity, at least one well-designed placebo-controlled trial has missed statistical significance, and no stem cell product currently has FDA approval for this indication. For now, stem cell therapy for diabetic foot ulcers is best understood as a promising, actively-researched option pursued through clinical trials — not yet a proven, approved standard treatment.